Clinical study of Mabthera (Rituximab)+chemotherapy for the treatment in non-Hodgkin's lymphoma (NHL)

Clinical study of Mabthera (Rituximab)+chemotherapy for the treatment in NHL

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000108

Enrollment

Unknown

Registered

2008-04-01

Start date

2003-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin's lymphoma (NHL)

Interventions

none:EPOCH

Experimental group:Chemo-treatment

Control Group:Chemo-treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who were certified NHL definitely with Pathologic diagnosis and CD20(+) and have no Contraindication of chemo-treatment.

Exclusion criteria

Exclusion criteria: The patients who could not be diagnosed definitely with Pathologic diagnosis or CD20(-) or have Contraindication of chemo-treatment

Design outcomes

Primary

Measure	Time frame
Overall surviva;	—

Secondary

Measure	Time frame
Disease free survival;Quality of life;	—

Countries

China

Contacts

Public ContactShen Yongqi

215871582@qq.com+86 0 13215871475

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026